Research programme: protein-protein interaction blockers - Vipergen

Drug Profile

Research programme: protein-protein interaction blockers - Vipergen

Latest Information Update: 06 Aug 2016

Price : $50

At a glance

  • Originator Vipergen ApS
  • Class Small molecules
  • Mechanism of Action Interleukin 17 receptor antagonists; Interleukin 6 receptor antagonists; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 06 Aug 2016 Early research is ongoing in Denmark
  • 08 Aug 2014 Early research in Cancer in Denmark (unspecified route)
  • 01 Sep 2013 Early research in Inflammation in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top